This week's Fierce Biotech is brought to you by SomaLogic.

Trouble viewing? Click here.

SomaLogic | Identify immunotherapy biomarkers non-invasively whitepaper

Identify immunotherapy biomarkers non-invasively with massively scaled proteomics

Circulating protein biomarkers are a promising avenue for predicting patient response to cancer immunotherapies. The SomaScan^® Assay

processes 7,000 blood-based protein measurements simultaneously. Learn how to apply the world’s largest protein assay to immuno-oncology procedures in our case study, "Circulating protein biomarkers are a promising avenue for predicting patient response to cancer immunotherapies."

Click to download the immunotherapy white paper

Explore the SomaScan^® Platform

The SomaScan^® Platform is your single platform for discovery, validation, and delivery. Using slow off-rate modified aptamers (called SOMAmer^® reagents) the SomaScan^® Assay provides 7,000 highly reproducible measurements of circulating proteins from a single sample of plasma, serum, or urine.

Interested in the SomaScan^® Assay?

Tests are indicated for Research Use Only (RUO) and have not been approved by the FDA.

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact [email protected] or call 202-824-5074.

You are currently subscribed as [email protected].
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor
New York, NY 10017

Identify immunotherapy biomarkers non-invasively with massively scaled proteomics

Explore the SomaScan® Platform

Interested in the SomaScan® Assay?

Explore the SomaScan^® Platform

Interested in the SomaScan^® Assay?